September 2024 issue
September 30, 2024 | The LSX World Conference USA, held in Boston, MA earlier this month, brought together some key leaders in the neurotechnology and medical technology sectors for a dynamic event focused on innovation, partnerships, investment, and commercialization strategies. The conference featured sessions on industry trends, investment insights, and the regulatory landscape. Among the standout events was the keynote panel with Becton, Dickinson CSO, Joseph Smith. In the session, titled “Sustained Success—A Holistic Review of MedTech in 2024,” industry leaders discussed market stability post-pandemic and the growing investor interest in medtech.
A key highlight of the conference was the panel discussion titled “Strategic Synergies: Scaling Through Industry Collaboration,” moderated by this editor. The panel featured Ana Maiques, CEO and co-founder of Neuroelectrics; Anh Hoang, CEO of Jana Care; Kurt Haggstrom, chief commercial officer of Synchron; and Jonathan Hoyt, executive director of global market development at Olympus Corporation of the Americas. Together, they shared their insights on how partnerships can drive growth, innovation, and resilience in a rapidly evolving healthcare landscape.
Leveraging Partnerships in a Complex Landscape
In a sector marked by both innovation and regulatory complexity, strategic partnerships play a vital role in helping companies scale and address challenges. Hoyt discussed how Olympus overcame its historic NIH (Not Invented Here) syndrome by shifting toward more open collaboration. This transformation, he noted, allowed Olympus to establish advisory services to foster relationships with startups and explore new detection technologies, recognizing that innovation cannot happen in isolation.
Synchron’s Haggstrom highlighted the unique challenges of partnering in the digital and medtech spaces. As Synchron develops its brain-computer interface technology, partnerships with tech firms are crucial. The convergence of medical devices and digital platforms requires technical collaboration across sectors, especially when integrating class 3 medical devices with new technology.
Hoang from Jana Care shared how their partnership with Roche has helped extend their resources, especially in manufacturing and regulatory processes. For startups with limited capacity, these types of collaborations offer a pathway to growth and the ability to scale quickly while filling gaps within larger companies.
AI, Data, and Beyond-the-Product Solutions
Another important theme was the role of AI and data in the future of healthcare. Maiques emphasized the need for innovation beyond traditional pharmaceuticals, particularly in the treatment of brain diseases like epilepsy. Her company, Neuroelectrics, is developing a non-invasive technology that monitors and stimulates brain activity in patients with treatment-resistant conditions. These personalized, tech-enabled solutions are driving the future of healthcare but require robust partnerships with both med-tech and pharmaceutical companies.
Haggstrom discussed the strategic importance of intellectual property and data-sharing in partnerships. Synchron, for example, carefully manages its IP to maintain flexibility across multiple platforms. This approach allows them to strategically integrate with large technology firms while protecting their core innovations. Hoyt added that data ownership is often a point of contention in partnerships, and suggested that start-ups begin with small wins and proof-of-concept projects to build trust and facilitate data-sharing without stalling progress.
Outsourcing and Its Implications for Growth
Outsourcing was another key discussion point, particularly for smaller companies looking to scale. Hoang highlighted how outsourcing certain operations, such as manufacturing and regulatory processes, has allowed Jana Care to remain lean while leveraging the expertise of larger partners like Roche. Maiques pointed out that while partnerships can be powerful, aligning long-term strategies with larger companies can be challenging due to internal restructuring. Despite these difficulties, she emphasized the value of persistence and outsourcing as tools for scaling.
MedTech’s Broader Themes
The LSX Boston event also explored broader themes through sessions such as “Promises in Pixels—Evaluating AI’s Impactful Delivery,” which examined the real-world impact of AI in healthcare. While AI is enhancing clinical operations, panelists raised concerns about whether it has fully met industry expectations. Other sessions, like “Keeping The Cash Flow,” provided valuable guidance to startups on navigating late-stage funding in a challenging economic environment.
Additionally, the conference addressed the regulatory landscape with a panel focused on how medtech companies can successfully navigate U.S. market access. This session highlighted the importance of early and robust regulatory planning for long-term success.
Collaboration and Innovation as Growth Catalysts
The healthcare industry’s complexity and the pace of innovation make collaboration essential for both start-ups and established companies. Partnerships that extend a company’s capabilities, leverage AI and data, and navigate outsourcing challenges are critical for long-term success. As Hoyt advised, companies should “define clear milestones and move quickly” when forming partnerships.
In an industry where the right collaboration can drive success, the LSX Boston conference reinforced the idea that strategic synergies are a catalyst for growth.
